A benefit-risk assessment of class III antiarrhythmic agents

Expert Opinion on Drug Safety

Volumn 3, Issue 6, 2004, Pages 559-577

  Elming, Hanne ^a,d   Brendorp, Bente ^b   Pehrson, Steen ^a   Pedersen, Ole Dyg ^c   Køber, Lars ^a   Torp Petersen, Christian ^c  

^a Rigshospitalet   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d NONE   (Denmark)

Author keywords

Antiarrhythmic; Benefit; Class III; Drug; Risk; Torsade de pointes (TdP)

Indexed keywords

ALDOSTERONE; AMILORIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; KETOCONAZOLE; METFORMIN; METOPROLOL; MW 593; MW 682; PROPAFENONE; QUINIDINE; SOTALOL; TRIAMTERENE; TRIMETHOPRIM;

BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVERSION; CLINICAL TRIAL; DEFIBRILLATOR; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; IMPLANTATION; LIVER TOXICITY; LUNG TOXICITY; MORTALITY; NEUROTOXICITY; PHYSICAL PERFORMANCE; PREVALENCE; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SHOCK; SINUS RHYTHM; SKIN TOXICITY; SUDDEN DEATH; SURVIVAL TIME; SYMPTOMATOLOGY; TACHYCARDIA; THYROID DISEASE; TORSADE DES POINTES;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; HEART CONDUCTION SYSTEM; HUMANS; IMIDAZOLIDINES; ION TRANSPORT; LIFE TABLES; MEMBRANE POTENTIALS; META-ANALYSIS; PHENETHYLAMINES; PIPERAZINES; RISK ASSESSMENT; SOTALOL; SULFONAMIDES; SURVIVAL ANALYSIS; TORSADES DE POINTES; TREATMENT OUTCOME;

EID: 8844267616     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.6.559     Document Type: Review

References (119)

1. BENJAMIN EJ, LEVY D, VAZIRI SM et al.: Independent risk factors for atria] fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271:840-844.
2. LEVY S, MAAREK M, COUMEL P et al.: Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation (1999) 99:3028-3035.
3. WYSE DG, WALDO AL, DIMARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
4. HOHNLOSER SH, KUCK KH, LILIENTHAL J et al.: Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 356:1789-1794.
5. MIDDLEKAUFF HR, STEVENSON WG, STEVENSON LW et al.: Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation (1991) 84:40-48.
6. CORLEY SD, EPSTEIN AE, DIMARCO JP et al.: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 109:1509-1513.
7. PEDERSEN OD, BRENDORP B, ELMING H et al.: Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) Study. Card. Electrophysiol. Rev. (2003) 7:220-224.
8. MOSS AJ, ZAREBA W, HALL WJ et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. (2002) 346 877-883.
9. SCHRON EB, EXNER DV, YAO Q et al.: Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation (2002) 105:589-594.
10. QI X, DORIAN P: Antiarrhythmic drugs and ventricular defibrillation energy requirements. Chin. Med. J. (1999) 112 1147-1152.
11. CLEOPHAS TJ, ZWINDERMAN AH: Beta-blockers and heart failure: meta-analysis of mortality trials. Int. J. Clin. Pharmacol. Ther. (2001) 39:383-388.
12. NO AUTHORS LISTED: The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation (1991) 84 1831-1851.
13. ACKERMAN MJ: The long QT syndrome: ion channel diseases of the heart. Mayo Clin. Proc. (1998) 73:250-269.
14. HOHNLOSER SH, SINGH BN: Proarrhythmia with Class III antiarrhythmic drugs. J. Cardiovasc. Electrophysiol. (1995) 6 920-936.
15. ZABEL M, HOHNLOSER SH, BEHRENS S et al.: Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J. Cardiovasc. Electrophysiol. (1997) 8:1148-1158.
16. OKAZAKI O, WEI D, HARUMI K et al.: A simulation study of Torsade de Pointes with M cells. J. Electrocardiol. (1998) 31 Suppl.):145-151.
17. TOMASELLI GF, ROSE J: Molecular aspects of arrhythmias associated with cardiomyopathies. Curr. Opin. Cardio. (2000) 15 202-208.
18. KOZHEVNIKOV DO, YAMAMOTO K, ROBOTIS D et al.: Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation (2002) 105:1128-1134.
19. DE MELLO WC: Cell coupling and impulse propagation in the failing heart. J. Cardiovasc. Electrophysiol. (1999) 10 1409-1420.
20. VISKIN S: Long QT syndromes and torsade de pointes. Lancet (1999) 354:1625-1633.
21. SURAWICZ B, PARIKH SR: Differences between ventricular repolarization in men and women: description, mechanism and implications. Ann. Noninvasive Electrocardiol. (2003) 8:333-340.
22. WOLBRETTE D, NACCARELLI G, CURTIS A et al.: Gender differences in arrhythmias. Clin. Cardiol. (2002) 25:49-56.
23. YAMREUDEEWONG W, DEBISSCHOP M, MARTIN LG et al.: Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. (2003) 26:421-438.
24. WOLBRETTE DL: Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am. J. Cardiol. (2003) 91:39D-44D.
25. BAYES DL, COUMEL P, LECLERCQ JF et al.: Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am. Heart. J. (1989) 117 151-159.
26. HOHNLOSER SH, WOOSLEY RL: Sotalol. N. Engl. J. Med. (1994) 331:31-38.
27. WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet (1996) 348:7-12.
28. SOUTHWORTH MR, ZAREMBSKI D, VIANA M et al.: Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. Am. J. Cardiol. (1999) 83:1629-1632.
29. PLEWAN A, LEHMANN G, NDREPEPA G et al.: Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol versus bisoprolol. Eur. Heart J. (2001) 22 1504-1510.
30. NO AUTHORS LISTED: Maintenance of sinus rhythm in patients with atria] fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J. Am. Coll. Cardiol. (2003) 42:20-29.
31. SINGH SN, SINGH BN, REDA DJ et al.: Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am. J. Cardiol. (2003) 92:468-472.
32. FUSTER V, RYDEN LE, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. (2001) 22 1852-1923.
33. JULIAN DG, PRESCOTT RJ, JACKSON FS et al.: Controlled trial of sotalol for one year after myocardial infarction. Lancet (1982) 1:1142-1147.
34. JUUL-MOLLER S, EDVARDSSON N, JAHNMATZ B et al.: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet (1992) 340 1421-1425.
35. THOMAS SP, GUY D, WALLACE E et al.: Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am. Heart (2004) 147:E3
36. MASON JW: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N. Engl. J. Med. (1993) 329 445-451.
37. PACIFICO A, HOHNLOSER SH, WILLIAMS JH et al.: Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N. Engl. J. Med. (1999) 340:1855-1862.
38. KUHLKAMP V, MEWIS C, MERMI J et al.: Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J. Am. Coll. Cardiol. (1999) 33:46-52.
39. KETTERING K, MEWIS C, DORNBERGER V et al.: Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin. Electrophysiol. (2002) 25 1571-1576.
40. MACNEIL DJ, DAVIES RO, DEITCHMAN D: Clinical safety profile of sotalol in the treatment of arrhythmias. Am. J. Cardiol. (1993) 72:44A-50A.
41. MACNEIL DJ: The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. Am. J. Cardiol. (1997) 80:90G-98G.
42. LEHMANN MH, HARDY S, ARCHIBALD D et al.: Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation (1996) 94:2535-2541.
43. CHUNG MK, SCHWEIKERT RA, WILKOFF BL et al.: Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J. Am. Coll. Cardiol. (1998) 32:169-176.
44. GWILT M, DALRYMPLE HW, BURGES RA et al.: Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J. Cardiovasc. Pharmacol. (1991) 17 376-385.
45. GWILT M, ARROWSMITH JE, BLACKBURN KJ et al.: UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther. (1991) 256:318-324.
46. + current by dofetilide. Circ. Res. (1993) 72 75-83.
47. KOBER L, BLOCH THOMSEN PE, MOLLER M et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356:2052-2058.
48. TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. (1999) 341:857-865.
49. BRENDORP B, ELMING H, JUN L et al.: QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation (2001) 103:1422-1427.
50. PRITCHETT EL, WILKINSON WE: Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am. Heart J. (1999) 138:994-997.
51. BORIANI G, LUBINSKI A, CAPUCCI A et al.: A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide versus sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur. Heart J. (2001) 22:2180-2191.
52. MAZUR A, ANDERSON ME, BONNEY S et al.: Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J. Am. Coll. Cardiol. (2001) 37:1100-1105.
53. BASHIR Y, THOMSEN PE, KINGMA JH et al.: Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am. J. Cardiol. (1995) 76:1040-1044.
54. KÖBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor randolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (1995) 333:1670-1676.
55. Package insert. Pfizer Laboratories. Tikosyn™ (dofetilide) (1999).
56. TRAN A, VICHIENDILOKKUL A, RACINE E et al.: Practical approach to the use and monitoring of dofetilide therapy. Am. J. Health Syst. Pharm. (2001) 58:2050-2059.
57. KODAMA I, KAMIYA K, TOYAMA J: Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. (1999) 84:20R-28R.
58. ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med. (2000) 342 913-920.
59. HILLEMAN DE, SPINLER SA: Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy (2002) 22:66-74.
60. NO AUTHORS LISTED: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet (1997) 350:1417-1424.
61. SIM I, MCDONALD KM, LAVORI PW et al.: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation (1997) 96:2823-2829.
62. FARRE J, ROMERO J, RUBIO JM et al.: Amiodarone and 'primary' prevention of sudden death: critical review of a decade of clinical trials. Am. J. Cardiol. (1999) 83:55D-63D.
63. NO AUTHORS LISTED: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am. J. Cardiol. (1993) 72:280-287.
64. DORIAN P, MANGAT I: Role of amiodarone in the era of the implantable cardioverter defibrillator. J. Cardiovasc. Electrophysiol. (2003) 14:S78-S81.
65. CONNOLLY SJ, GENT M, ROBERTS RS et al.: Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 101:1297-1302.
66. NO AUTHORS LISTED: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med. (1997) 337:1576-1583.
67. STRICKBERGER SA, HUMMEL JD, BARTLETT TG et al.: Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J. Am. Coll. Cardiol. (2003) 41:1707-1712.
68. KUHLKAMP V, MEWIS C, SUCHALLA R et al.: Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int. J. Cardiol. (1999) 69:271-279.
69. DORIAN P, CASS D, SCHWARTZ B et al.: Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N. Engl. J. Med. (2002) 346:884-890.
70. KUDENCHUK PJ, COBB LA, COPASS MK et al.: Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N. Engl. J. Med. (1999) 341:871-878.
71. GIRI S, WHITE CM, DUNN AB et al.: Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet (2001) 357:830-836.
72. YAGDI T, NALBANTGIL S, AYIK F et al.: Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. (2003) 125:1420-1425.
73. KURALAY E, CINGOZ F, KILIC S et al.: Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur. J. Cardiothorac. Surg. (2004) 25:224-230.
74. CRYSTAL E, CONNOLLY SJ, SLEIK K et al.: Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation (2002) 106:75-80.
75. WURDEMAN RL, MOOSS AN, MOHIUDDIN SM et al.: Amiodarone versus sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. Chest (2002) 121:1203-1210.
76. BRACHMANN J, SCHERLAG BJ, ROSENSHTRAUKH LV et al.: Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation (1983) 68 846-856.
77. HOHNLOSER SH, KLINGENHEBEN T, SINGH BN: Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann. Intern. Med. (1994) 121:529-535.
78. ESSEBAG V, HADJIS T, PLATT RW et al.: Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J. Am. Coll. Cardiol. (2003) 41:249-254.
79. VORPERIAN VR, HAVIGHURST TC, MILLER S et al.: Adverse effects of low dose amiodarone: a meta-analysis. J. Am. Coll. Cardiol (1997) 30:791-798.
80. BOUTITIE F, BOISSEL JP, CONNOLLY SJ et al.: Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation (1999) 99:2268-2275.
81. CAIRNS JA, CONNOLLY SJ, ROBERTS R et al.: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet (1997) 349:675-682.
82. CRYSTAL E, KAHN S, ROBERTS R et al.: Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). J. Thorac. Cardiovasc. Surg. (2003) 125 633-637.
83. THOMAS D, KATHOFER S, ZHANG W et al.: Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br. J. Pharmacol. (2003) 140:996-1002.
84. PANTOS C, MOUROUZIS I, DELBRUYERE M et al.: Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Eur. J. Pharmacol. (2002) 444:191-196.
85. TOUBOUL P, BRUGADA J, CAPUCCI A et al.: Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J. (2003) 24:1481-1487.
86. SINGH S: Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J. Interv. Card. Electrophysiol. (2004) 10(Suppl. 1):71-76.
87. SUN W, SARMA JS, SINGH BN: Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation (1999) 100 2276-2281.
88. AMOS GJ, JACOBSON I, DUKER G, CARLSSON L: Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52. J. Cardiovasc. Electrophysiol. (2003) 14:651-658.
89. STAMBLER BS, WOOD MA, ELLENBOGEN KA et al.: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation (1996) 94:1613-1621.
90. ELLENBOGEN KA, STAMBLER BS, WOOD MA et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J. Am. Coll. Cardiol. (1996) 28:130-136.
91. VANDERLUGT JT, MATTIONI T, DENKER S et al.: Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation (1999) 100:369-375.
92. BERNARD EO, SCHMID ER, SCHMIDLIN D et al.: Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit. Care Med. (2003) 31:1031-1034.
93. ANTONICELLI R, TESTARMATA P, RECANATINI A: Ibutilide in rapid conversion of atrial flutter in octogenarians. Drugs Aging (2002) 19:787-791.
94. KOWEY PR, VANDERLUGT JT, LUDERER JR: Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am. J. Cardiol. (1996) 78:46-52.
95. MAKKAR RR, FROMM BS, STEINMAN RT et al.: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 270:2590-2597.
96. CARON MF, KLUGER J, TSIKOURIS JP et al.: Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy (2003) 23:296-300.
97. GLATTER K, YANG Y, CHATTERJEE K et al.: Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation (2001) 103 253-257.
98. YAO JA, TSENG GN: Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels. J. Cardiovasc. Electrophysiol. (1997) 8:184-198.
99. PRITCHETT EL, SCHULTE MC, SCHNELL D et al.: Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. J. Clin. Pharmacol. (2002) 42:388-394.
100. COREY AE, AGNEW JR, VALENTINE SN et al.: Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. Br. J. Clin. Pharmacol. (2002) 54:449-452.
101. CONNOLLY SJ, SCHNELL DJ, PAGE RL et al.: Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am. J. Cardiol. (2001) 88:974-979.
102. CONNOLLY SJ, SCHNELL DJ, PAGE RL et al.: Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. Am. Heart J. (2003) 146:489-493.
103. PAGE RL, TILSCH TW, CONNOLLY SJ et al.: Asymptomatic or 'silent' atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation (2003) 107 1141-1145.
104. CAMM AJ, PRATT CM, SCHWARTZ PJ et al.: Mortality in patients after a recent myocardial infarction. A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation (2004) 109:990-996.
105. SINGER I, AL KHALIDI H, NIAZI I et al.: Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J. Am. Coll. Cardiol. (2004) 43:39-43.
106. NACCARELLI GV, WOLBRETTE DL, KHAN M et al.: Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am. J. Cardiol. (2003) 91:15D-26D.
107. BENDITT DG, WILLIAMS JH, JIN J et al.: Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am. J. Cardiol. (1999) 84:270-277.
108. BELLANDI F, SIMONETTI I, LEONCINI M et al.: Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. (2001) 88:640-645.
109. REIMOLD SC, CANTILLON CO, FRIEDMAN PL et al.: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. (1993) 71:558-563.
110. JUUL-MOLLER S, EDVARDSSON N, REHNQVIST-AHLBERG N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation (1990) 82 1932-1939.
111. GREENBAUM RA, CAMBELL TJ, CHANNER KS et al.: EMERALD. Circulation (1998) 17:633. (Abstract).
112. SINGH S, ZOBLE RG, YELLEN L et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385-2390.
113. PEDERSEN OD, BAGGER H, KELLER N et al.: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation (2001) 104:292-296.
114. BURKART F, PFISTERER M, KIOWSKI W et al.: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J. Am. Coll. Cardiol. (1990) 16:1711-1718.
115. CEREMUZYNSKI L, KLECZAR E, KRZEMINSKA-PAKULA M et al.: Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J. Am. Coll. Cardiol. (1992) 20:1056-1062.
116. NAVARRO-LOPEZ F, COSIN J, MARRUGAT J et al.: Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. Am. J. Cardiol. (1993) 72:1243-1248.
117. JULIAN DG, CAMM AJ, FRANGIN G et al.: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet (1997) 349:667-674.
118. SINGH SN, FLETCHER RD, FISHER SG et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl. J. Med. (1995) 333:77-82.
119. DOVAL HC, NUL DR, GRANCELLI HO et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet (1994) 344:493-498.